Low stock COA
NOVALYTE
LABS
LABS
NOVALYTELABS
Tesamorelin10mg · RESEARCH USE ONLY
Tesamorelin10mg · RESEARCH USE ONLY
In stock COA DOCUMENT SLOT
Growth ResearchTesamorelin
Synthetic GHRH analog studied for growth hormone secretion dynamics and somatotroph cell signalling.
Research catalogueLaboratory-use positioning
Batch documentationBatch certificate supplied with order
Order trackingFrom payment to dispatch
Product information
CompoundTesamorelin
Presentation10mg vial
CategoryGrowth Research
AvailabilityIn stock
Batch COACertificate supplied with order
€62.90
For research use only. Not for human consumption, diagnostic, therapeutic or veterinary use.
Overview
Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) consisting of the full 44-amino-acid sequence of endogenous GHRH with a trans-3-hexenoic acid modification at the N-terminus. This structural modification improves resistance to enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV) while preserving full biological activity at the GHRH receptor. Tesamorelin is the only FDA-approved GHRH analog and has been the subject of multiple clinical trials investigating its effects on GH dynamics and body composition.
Mechanism of Action
Tesamorelin binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating the Gs-adenylate cyclase-cAMP-PKA signalling cascade. This triggers calcium influx through voltage-gated calcium channels, leading to exocytosis of stored growth hormone granules. Importantly, tesamorelin preserves the physiological pulsatile pattern of GH release and maintains negative feedback regulation by IGF-1 and somatostatin. The trans-hexenoic acid group protects the N-terminal tyrosine from DPP-IV cleavage.
Research Applications
- GH secretion kinetics and pulsatility research
- Pituitary somatotroph cell signalling studies
- Visceral adiposity and lipodystrophy research
- GHRH receptor pharmacology investigation
- IGF-1 axis and feedback loop studies